{"mainPropery":{"diseaseId":9240,"diseaseName":"Childhood acute lymphoblastic leukemia","hasGardWebPage":true,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/9240/childhood-acute-lymphoblastic-leukemia","synonyms":["Childhood acute lymphocytic leukemia","Pediatric acute lymphoblastic leukemia","Childhood ALL"],"synonyms-with-source":[{"name":"Childhood acute lymphocytic leukemia","source":""},{"name":"Pediatric acute lymphoblastic leukemia","source":""},{"name":"Childhood ALL","source":""}],"identifiers":[{"identifierType":"ORPHANET","identifierId":"513"},{"identifierType":"UMLS","identifierId":"C0023452"}]},"diseaseCategories":[{"diseaseTypeId":1,"diseaseTypeName":"Rare Cancers"}],"organizations":[{"resourceID":570,"resourceName":"Leukemia and Lymphoma Society","abbreviation":"","address1":"3 International Drive, Suite 200","address2":"","address3":"","address4":"","address5":"","city":"Rye Brook","state":"NY","zip":"10573","country":"United States","phone":"1-(888) 557-7177 (general)","tty":"","tollFree":"1-(800) 955-4572 (patients and families)","fax":"","email":"https://www.lls.org/content/contact-us","url":"https://www.lls.org/","freeText":""},{"resourceID":2773,"resourceName":"Leukaemia Foundation","abbreviation":"","address1":"","address2":"","address3":"","address4":"","address5":"","city":"","state":"","zip":"","country":"","phone":"","tty":"","tollFree":"","fax":"","email":"info@leukaemia.org.au","url":"http://www.leukaemia.org.au/"}],"resource descriptions":[{"id":9,"resourceId":12,"resourceName":"ClinicalTrials.gov","descriptionText":"<a href='https://www.clinicaltrials.gov/ct2/results?term=acute+lymphocytic+leukemia&Search=Search' target='_blank'>ClinicalTrials.gov</a> lists trials that are related to Childhood acute lymphoblastic leukemia. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies. <br />\r\n<br />\r\n<em><strong>Please note:</strong>&nbsp;Studies listed on the&nbsp;ClinicalTrials.gov&nbsp;website are listed for informational purposes only; being listed does not reflect an endorsement by GARD or the NIH. We strongly recommend that you talk with a trusted healthcare provider before choosing to participate in any clinical study.</em>","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"},{"id":1529,"resourceId":2128,"resourceName":"MedlinePlus","descriptionText":"<a href='http://www.nlm.nih.gov/medlineplus/ency/article/000541.htm' target='_blank'>MedlinePlus</a> was designed by the National Library of Medicine to help you research your health questions, and it provides more information about this topic.\r\n<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1531,"resourceId":2162,"resourceName":"Medscape Reference","descriptionText":"<a href='http://emedicine.medscape.com/article/990113-overview' target='_blank'>Medscape Reference</a> provides information on this topic. You may need to register to view the medical textbook, but registration is free.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1534,"resourceId":2165,"resourceName":"Orphanet","descriptionText":"<a href='http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=513' target='_blank'>Orphanet</a> is a European reference portal for&nbsp;information on rare diseases and orphan drugs. Access to this database is free of charge.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1543,"resourceId":2171,"resourceName":"National Cancer Institute","descriptionText":"The <a href='http://www.cancer.gov/cancertopics/pdq/treatment/childALL/Patient' target='_blank'>National Cancer Institute</a> provides the most current information on cancer for patients, health professionals, and the general public.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1545,"resourceId":2173,"resourceName":"Merck Manual","descriptionText":"The <a href='http://www.merckmanuals.com/home/blood-disorders/leukemias/acute-lymphocytic-leukemia-all' target='_blank'>Merck Manual</a> provides information on this condition for patients and caregivers.&nbsp;","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1650,"resourceId":500,"resourceName":"Cancer.net","descriptionText":"<a href='http://www.cancer.net/cancer-types/leukemia-acute-lymphoblastic-all-childhood/overview' target='_blank'>Cancer.net</a> provides oncologist-approved cancer information from the American Society of Clinical Oncology and has information about Childhood acute lymphoblastic leukemia.","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1764,"resourceId":2924,"resourceName":"Mayo Clinic","descriptionText":"The <a href='http://www.mayoclinic.org/diseases-conditions/acute-lymphocytic-leukemia/basics/definition/con-20042915' target='_blank'>Mayo Clinic</a> Web site provides further information on Childhood acute lymphoblastic leukemia.","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":2135,"resourceId":3342,"resourceName":"Monarch Initiative","descriptionText":"The <a href='https://monarchinitiative.org/disease/OMIM:613065' target='_blank'>Monarch Initiative</a> brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch&rsquo;s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":2160,"resourceId":3368,"resourceName":"Patient Access Network Foundation","descriptionText":"<a href='https://panfoundation.org/index.php/en/patients/assistance-programs/philadelphia-chromosome-positive-acute-lymphoblastic-leukemia' target='_blank'>Patient Access Network Foundation</a> (PAN Foundation) has Assistance Programs for those with health insurance who reside in the United States. The disease fund status can change over time, so you may need to check back if funds are not currently available.&nbsp;","resourceClassificationName":"Living With","resourceClassificationSectionName":"Financial Resources"},{"id":2163,"resourceId":3372,"resourceName":"Good Days","descriptionText":"<a href='https://www.mygooddays.org/patients/diseases-covered/chronic-iron-overload' target='_blank'>Good Days</a> provides help to patients with life-altering conditions. Assistance includes help with the cost of medications and travel.","resourceClassificationName":"Living With","resourceClassificationSectionName":"Financial Resources"}],"overviewQuestion":{"questionId":8596,"questionText":"What is childhood acute lymphoblastic leukemia?","answerText":"<strong>Childhood acute lymphoblastic leukemia</strong> (ALL) is a type of cancer of the blood and bone marrow, and the most common type of cancer in children. In children with this condition, too many stem cells made by the bone marrow become <a href=\"http://www.cancer.gov/common/popUps/popDefinition.aspx?id=CDR0000302475&amp;version=Patient&amp;language=English\" target=\"_blank\">lymphoblasts</a>, <a href=\"http://www.cancer.gov/common/popUps/popDefinition.aspx?id=CDR0000044953&amp;version=Patient&amp;language=English\" target=\"_blank\">B lymphocytes</a>, or <a href=\"http://www.cancer.gov/common/popUps/popDefinition.aspx?id=CDR0000044928&amp;version=Patient&amp;language=English\" target=\"_blank\">T lymphocytes</a>. These cells do not function normally and have trouble fighting off infections. Signs and symptoms may include fever; easy bruising or bleeding; bone or joint pain; painless lumps in the neck, underarm, stomach, or groin; weakness; fatigue; and/or loss of appetite. Treatment depends on several factors and may include <a href=\"http://www.cancer.gov/common/popUps/popDefinition.aspx?id=CDR0000045650&amp;version=Patient&amp;language=English\" target=\"_blank\">combination chemotherapy</a>, <a href=\"http://www.cancer.gov/common/popUps/popDefinition.aspx?id=CDR0000270742&amp;version=Patient&amp;language=English\" target=\"_blank\">targeted therapy</a>, and/or <a href=\"http://www.cancer.gov/common/popUps/popDefinition.aspx?id=CDR0000046695&amp;version=Patient&amp;language=English\" target=\"_blank\">stem cell transplant</a>.[8703] <br />\r\n<br />\r\nOn August 30 2017, Kymriah became the first gene therapy approved by the FDA. Kymriah is now an option for children and young adults up to 25 years old with B-Cell precursor ALL that has proven resistant to other treatments or has relapsed two or more times.[13818]","dateModified":"2017-09-18T00:00:00"},"basicQuestions":[{"questionId":8598,"questionText":"What is the long-term outlook for people with childhood acute lymphoblastic leukemia?","answerText":"The long-term outlook (prognosis) for people with childhood acute lymphoblastic leukemia (ALL), including the potential for long-term cure, depends on the severity of the condition, laboratory features, and treatment. Factors that may affect prognosis include the age and white blood cell count at the time of diagnosis; biologic characteristics of the leukemia cells; response to chemotherapy; and the amount of cancer cells that remain during treatment or remission. This information can be used to assess the risk for each affected person.[8708]<br />\r\n<br />\r\nOverall, the cure rate for childhood ALL is more than 80%. Five-year survival rates for children rose to 90% from 2000-2005. Improvement in survival has been seen for all age groups of children, except for infants younger than 1 year (who have a poor outcome). In low-income countries, treatment results have been less encouraging.[8708]\r\n<br />\r\n<br />\r\nPotential acute complications can include <a href=\"http://www.cancer.gov/dictionary?cdrid=626342\" target=\"_blank\">tumor lysis syndrome</a>, renal failure, <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/000666.htm\" target=\"_blank\">sepsis</a>, bleeding, thrombosis (development of a blood clot), inflammation of the <a href=\"http://www.merriam-webster.com/medlineplus/cecum\" target=\"_blank\">cecum</a> (typhlitis), <a href=\"http://www.merriam-webster.com/medlineplus/neuropathy\" target=\"_blank\">neuropathy</a>, <a href=\"http://www.ninds.nih.gov/disorders/encephalopathy/encephalopathy.htm\" target=\"_blank\">encephalopathy</a>, or <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003200.htm\" target=\"_blank\">seizures</a>.[8708]<br />\r\n<br />\r\nLifelong follow-up is necessary because survivors may have late complications from the treatment, such as secondary malignancy, short stature, growth hormone deficiency, learning disabilities, or cognitive defects.[8708]","dateModified":"2015-04-20T11:21:00","resourceClassificationName":"Prognosis","references":[{"referenceId":8708,"authors":"Vikramjit S Kanwar","articleTitle":"Pediatric Acute Lymphoblastic Leukemia","bookWebsiteJournalTitle":"Medscape","date":"December 5, 2014","volume":"","pages":"","url":"http://emedicine.medscape.com/article/990113-overview","authors2":"","placeOfPublication":"","publisher":""}]}],"references":[],"relatedDiseases":[{"relatedDiseaseId":522,"relatedDiseaseName":"Acute lymphoblastic leukemia","relation":"Parent","isRare":true,"hasGardPage":true}],"gardCases":[{"caseId":51128,"abbreviatedInquiry":"Is this considered a rare disease? What makes this disease rare? What are the outcomes for children diagnosed with this disease? What are some long term effects that can be expected?","caseQuestions":[{"questionId":8597,"questionText":"Is childhood acute lymphoblastic leukemia a rare disease?","answerText":"Even though childhood acute lymphoblastic leukemia (ALL) is the most common type of cancer in children, it is still considered a rare disease. In the Unites States, a disease is defined as rare when it affects fewer than 200,000 people at a given time.[8704]<br />\r\n<br />\r\nThere are approximately 2,900 children and adolescents younger than 20 years of age diagnosed with ALL each year in the United States. Over the past 25 years, there has been a gradual increase in the incidence of ALL. The incidence is highest among children age 2 to 3 years. It appears to be highest in Hispanic children, and is substantially higher in white children than in black children.[8705]","dateModified":"2015-04-20T11:20:00","references":[{"referenceId":8704,"authors":"","articleTitle":"Frequently Asked Questions About Rare Diseases","bookWebsiteJournalTitle":"NHGRI","date":"February 27, 2012","volume":"","pages":"","url":"http://www.genome.gov/27531963","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":8705,"authors":"","articleTitle":"Childhood Acute Lymphoblastic Leukemia Treatment (PDQ®)","bookWebsiteJournalTitle":"National Cancer Institute","date":"April 8, 2015","volume":"","pages":"","url":"http://www.cancer.gov/cancertopics/pdq/treatment/childALL/HealthProfessional","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":8598,"questionText":"What is the long-term outlook for people with childhood acute lymphoblastic leukemia?","answerText":"The long-term outlook (prognosis) for people with childhood acute lymphoblastic leukemia (ALL), including the potential for long-term cure, depends on the severity of the condition, laboratory features, and treatment. Factors that may affect prognosis include the age and white blood cell count at the time of diagnosis; biologic characteristics of the leukemia cells; response to chemotherapy; and the amount of cancer cells that remain during treatment or remission. This information can be used to assess the risk for each affected person.[8708]<br />\r\n<br />\r\nOverall, the cure rate for childhood ALL is more than 80%. Five-year survival rates for children rose to 90% from 2000-2005. Improvement in survival has been seen for all age groups of children, except for infants younger than 1 year (who have a poor outcome). In low-income countries, treatment results have been less encouraging.[8708]\r\n<br />\r\n<br />\r\nPotential acute complications can include <a href=\"http://www.cancer.gov/dictionary?cdrid=626342\" target=\"_blank\">tumor lysis syndrome</a>, renal failure, <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/000666.htm\" target=\"_blank\">sepsis</a>, bleeding, thrombosis (development of a blood clot), inflammation of the <a href=\"http://www.merriam-webster.com/medlineplus/cecum\" target=\"_blank\">cecum</a> (typhlitis), <a href=\"http://www.merriam-webster.com/medlineplus/neuropathy\" target=\"_blank\">neuropathy</a>, <a href=\"http://www.ninds.nih.gov/disorders/encephalopathy/encephalopathy.htm\" target=\"_blank\">encephalopathy</a>, or <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003200.htm\" target=\"_blank\">seizures</a>.[8708]<br />\r\n<br />\r\nLifelong follow-up is necessary because survivors may have late complications from the treatment, such as secondary malignancy, short stature, growth hormone deficiency, learning disabilities, or cognitive defects.[8708]","dateModified":"2015-04-20T11:21:00","resourceClassificationName":"Prognosis","references":[{"referenceId":8708,"authors":"Vikramjit S Kanwar","articleTitle":"Pediatric Acute Lymphoblastic Leukemia","bookWebsiteJournalTitle":"Medscape","date":"December 5, 2014","volume":"","pages":"","url":"http://emedicine.medscape.com/article/990113-overview","authors2":"","placeOfPublication":"","publisher":""}]}]}],"news":[{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[],"medicalProducts":[{"productId":687,"genericName":"Tisagenlecleucel-T","tradeName":"Kymriah","tradeLink":"https://www.us.kymriah.com/acute-lymphoblastic-leukemia-children/","manufacturer":"","sponsor":"Novartis Pharmaceuticals Corporation","indication":"August 2017 approved for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.","drugInformationLink":"https://druginfo.nlm.nih.gov/drugportal/name/kymriah","medlinePlusLink":"https://medlineplus.gov/druginfo/meds/a617053.html"},{"productId":76,"genericName":"Dasatinib","tradeName":"Sprycel","tradeLink":"https://www.sprycel.com/","manufacturer":"","sponsor":"Bristol-Myers Squibb Company","indication":"December 2018, dasatinib (Sprycel) was approved for the treatment of pediatric patients 1 year of age and older with Ph+ CML in chronic phase and newly diagnosed Ph+ ALL in combination with chemotherapy. Previously in June 2013, it was approved for treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy.","drugInformationLink":"https://druginfo.nlm.nih.gov/drugportal/rn/863127-77-9","medlinePlusLink":"https://medlineplus.gov/druginfo/meds/a607063.html"},{"productId":82,"genericName":"Teniposide","tradeName":"Vumon","tradeLink":"","manufacturer":"","sponsor":"Bristol-Myers Squibb Co","indication":"July 1992, teniposide (Vumon) was approved for Induction therapy in patients with refractory childhood acute lymphoblastic leukemia when used in combination with other approved anticancer agents.","drugInformationLink":"https://druginfo.nlm.nih.gov/drugportal/name/vumon","medlinePlusLink":"https://medlineplus.gov/druginfo/meds/a692045.html"},{"productId":676,"genericName":"Methotrexate oral solution","tradeName":"Xatmep","tradeLink":"http://silvergatepharma.com/index.php/2017/04/26/xatmep/","manufacturer":"","sponsor":"Silvergate Pharmaceuticals, Inc.","indication":"April 2017, methotrexate oral solution (Xatmep) was approved for the treatment of pediatric patients with acute lymphoblastic leukemia (ALL) as a component of a combination chemotherapy maintenance regimen.","drugInformationLink":"https://druginfo.nlm.nih.gov/drugportal/name/xatmep","medlinePlusLink":""}],"EncodedName":"Childhood_acute_lymphoblastic_leukemia"}